LateTIME: A Phase-II, Randomized, Double-Blinded, Placebo-Controlled, Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells 2 to 3 Weeks after Acute Myocardial Infarction

A realistic goal for cardiac cell therapy may be to attenuate left ventricular remodeling following acute myocardial infarction to prevent the development of congestive heart failure. Initial clinical trials of cell therapy have delivered cells 1 to 7 days after acute myocardial infarction. However,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Traverse, Jay H., Henry, Timothy D., Vaughan, Douglas E., Ellis, Stephen G., Pepine, Carl J., Willerson, James T., Zhao, David X.M., Simpson, Lara M., Penn, Marc S., Byrne, Barry J., Perin, Emerson C., Gee, Adrian P., Hatzopoulos, Antonis K., McKenna, David H., Forder, John R., Taylor, Doris A., Cogle, Christopher R., Baraniuk, Sarah, Olson, Rachel E., Jorgenson, Beth C., Sayre, Shelly L., Vojvodic, Rachel W., Gordon, David J., Skarlatos, Sonia I., Moyè, Lemuel A., Simari, Robert D.
Formato: Artigo
Idioma:Inglês
Publicado em: Texas Heart Institute 2010
Assuntos:
Clinical Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2929864/
https://ncbi.nlm.nih.gov/pubmed/20844613
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados